Early Generic Semaglutide in Canada—Implications for US Patients and Policy

This Viewpoint explores the emergence of generic versions of semaglutide in Canada and the implications for US patients.

Corresponding Author: Reed F. Beall, PhD, University of Calgary, 2500 University Dr NW Calgary, AB T2N 4Z6, Canada (reed.beall@ucalgary.ca).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.